Shereen Medhat Mohammed Elsayed Nassar
Quick facts
Phase 3 pipeline
- Rituximab (Mabthera) · Oncology, Immunology
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: